AstraZeneca data at ASN Kidney Week reinforces urgent need for early screening of chronic kidney disease and benefits of earlier treatment for patients and healthcare systems
REVEAL-CKD data show alarming prevalence of undiagnosed Stage 3 chronic kidney disease across France, Germany, Italy, Japan and US.Findings from INSIDE-CKD demonstrate that Farxiga could cut 33 percent of healthcare costs by delaying disease progression and reducing incidence of cardiorenal events.AstraZeneca, a leader in cardiorenal research, presented new data at the American Society of Nephrology (ASN) Kidney Week 2022 in Orlando, Florida, US on the importance of earlier screening and diagnosis of chronic kidney disease (CKD) and the impact of Farxiga on reducing healthcare costs[1,2].